Raymond James Institutional Investors Conference

March 2024

CONFIDENTIAL - DO NOT DISTRIBUTE

Safe harbor statement

This presentation contains forward-looking statements that are based on our management's beliefs and assumptions and on information currently

available to management. We intend for such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements include information concerning our possible or assumed strategy, future operations, financing plans, operating model, financial position, future revenues, gross margin, operating margin, projected costs, competitive position, industry environment, potential growth opportunities, potential market opportunities, plans and objectives of management and the effects of competition on our business. This presentation also contains estimates and other statistical data made by independent parties relating to market size and growth and other data about our industry. This data involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates.

Forward-looking statements include all statements that are not historical facts and can be identified by terms such as "anticipates," "believes," "could," "seeks," "estimates," "targets," "guidance," "expects," "intends," "may," "plans," "potential," "predicts," "prospects," "projects," "should," "will," "would" or

similar expressions and the negatives of those terms, although not all forward-looking statements contain these identifying words. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. We cannot guarantee that we will achieve the plans, intentions, or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. We assume no obligation to update any such forward-looking statement after the date of this presentation or to conform these forward-looking statements to actual results.

The risks and uncertainties that may cause actual results to differ materially from our current expectations are more fully described in our annual report on Form 10-K for the period ended December 31, 2023, as filed with the Securities and Exchange Commission on February 8, 2024, and our other reports, each as filed with the Securities and Exchange Commission.

This presentation contains non-GAAP financial measures. These non-GAAP financial measures include organic revenue, non-GAAP gross margin, non-GAAP operating margin, and adjusted EBITDA margin. We report non-GAAP financial measures in addition to, and not as a substitute for, or superior to, measures of financial performance prepared in accordance with GAAP. These non-GAAP financial measures are not based on any comprehensive set of accounting rules or principles, differ from GAAP measures with the same names, and may differ from non-GAAP financial measures with the same or similar names that are used by other companies. We believe that non-GAAP financial measures should only be used to evaluate our results of operations in conjunction with the corresponding GAAP financial measures. We encourage investors to carefully consider our results under GAAP, as well as our supplemental non-GAAP information and the reconciliations between these presentations, to more fully understand our business. We have not reconciled the non-GAAP financial measures in this presentation because certain items that impact these measures are not available without unreasonable effort.

2

A global crisis that remains uncontrolled

Diabetes diagnosis and cost

Adults (aged 20-79) with diabetes globally1

783m

in 2045E

537m

People diagnosed with diabetes

have ~2.6x higher expenses than those without2

463m

in 2019

151m

in 2000

in 2021

More than 1 in 4 US health care

dollars are spent on people with diabetes2

  1. IDF Atlas, 10th edition (2021).
  2. 2022 ADA Economic Costs of Diabetes in the US. US annual healthcare cost per person with diabetes was ~$20K in 2022.

3

Intermittent glucose monitoring

is not enough for diabetes management…

Glucose (mg/dl)

340

SMBG*

320

300

280

260

240

220

200

180

160

140

120

100Target Glucose Range

80

60

40

20

0

0

2

4

6

8

10

12

14

16

18

20

22

24

Time (hours)

*As compared to Self Monitoring of Blood Glucose (SMBG)

4

…and CGM has become standard

of care1 for all stages of insulin-use

Glucose (mg/dl)

340

320

300

280

260

240

APPROXIMATELY 17 HOURS ABOVE TARGET RANGE, INCLUDING

~6 HOURS IN SEVERE HYPERGLYCEMIA (>250 mg/dl)

220

200

AVG GLUCOSE:

180

185 mg/dl

160

140

Target

120

100

Glucose Range

80

60

40

20

0

0

2

4

6

8

10

12

14

16

18

20

22

24

Time (hours)

*As compared to Self Monitoring of Blood Glucose (SMBG). Illustrative example drawn from a pilot program involving Dexcom CGM use in Type 2 NIIT. 1. As defined by ADA Standards of Care in Diabetes - 2024.

5

We can do more

6

Pioneering the CGM industry

First hypo alert setting to increase user safety

First approval of dedicated app to share glucose data with a caregiver

First to deliver single-digitMARD accuracy levels

First approval to send glucose data directly to smartphone

First to enable users to monitor glucose levels on Apple Watch First approval to replace fingersticks in treatment decisions

First integrated CGM (iCGM) device, enabling integration with Automated Insulin Delivery (AID) systems

First clearance of real-timeAPIs expanding connectivity leadership First CGM to connect directly to Apple Watch

*Image shown does not include required overpatch. Please be sure to follow instructions for using the overpatch.

7

OUR MISSION

Empowering people to take control of health

*Image shown does not include required overpatch. Please be sure to follow instructions for using the overpatch.

2023 performance

Strong revenue growth

2023 revenue of $3.62 billion, representing growth of greater

than 24%

Grew the active Dexcom base by ~35% during 2023. Now serving approximately 2.3 million customers globally

Margin expansion

Approximately 400 basis points of operating expense leverage

Expanded access

Clinical evidence and product portfolio drove significantly greater access to Dexcom CGM

Scaled capacity

Initiated commercial production at new flagship manufacturing site in Malaysia, which will support years of growth

9

2024 outlook

FY24 guidance

Revenue of

$4.15 − 4.35 billion

~16 - 21% Organic Growth1

Non-GAAP

Non-GAAP

Adjusted

gross margin

operating margin

EBITDA margin

~63 − 64%

~20%

~29%

Objectives & considerations

  • Ongoing conversion of G6 to G7 within customer base
  • Extending momentum of 2023 launch in type 2 basal and non-insulinhypo populations
  • Expansion of Dexcom ONE into new geographies
    • Transition to G7 form factor underway
  • Summer 2024 launch of 15-daynon-insulin product, with modest contribution included in 2024 guidance
    • Expected to launch as cash-pay while we build evidence for reimbursement
  • Strong year-over-year operating expense leverage

We built momentum in 2023 and look forward to

extending our addressable market with tailored solutions in 2024

1. Assumes divestiture of certain non-CGM assets that accounted for approximately $30 million of revenue in fiscal year 2023. 2024 organic growth expectation calculated excluding that contribution from the 2023 base.

10

Attachments

  • Original Link
  • Original Document
  • Permalink

Disclaimer

DexCom Inc. published this content on 08 March 2024 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 08 March 2024 19:13:09 UTC.